PRO044 SC

( DrugBank: - / KEGG DRUG: - )

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
113	筋ジストロフィー	3

113. 筋ジストロフィー

臨床試験数 : 646 / 薬物数 : 471 - (DrugBank : 105) / 標的遺伝子数 : 59 - 標的パスウェイ数 : 170

trials per page:

Showing 1 to 3 of 3 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02958202 (ClinicalTrials.gov)	April 2016	27/10/2016	Extension Study of BMN 044 in Duchenne Muscular Dystrophy (DMD)	A Multi Center, Multi National, Open Label, Extension Study to Evaluate the Long-term Efficacy and S ...	Duchenne Muscular Dystrophy	Drug: BMN 044 IV 6 mg/kg;Drug: BMN 044 IV 9 mg/kg;Drug: BMN 044 SC 6 mg/kg	BioMarin Pharmaceutical	NULL	Terminated	5 Years	N/A	Male	7	Phase 2	Belgium;Italy;Netherlands;Sweden
2	NCT02329769 (ClinicalTrials.gov)	December 2014	22/12/2014	Open Label, Extension Study of PRO044 in Duchenne Muscular Dystrophy (DMD)	A Phase II, Open Label, Extension Study to Assess the Effect of PRO044in Patients With Duchenne Musc ...	Duchenne Muscular Dystrophy	Drug: PRO044 SC 6 mg/kg;Drug: PRO044 IV 6 mg/kg;Drug: PRO044 IV 9 mg/kg	BioMarin Pharmaceutical	NULL	Terminated	9 Years	20 Years	Male	15	Phase 2	Belgium;Italy;Netherlands;Sweden
3	NCT01037309 (ClinicalTrials.gov)	December 2009	21/12/2009	Phase I/II Study of PRO044 in Duchenne Muscular Dystrophy (DMD)	A Phase I/IIa, Open Label, Escalating Dose, Pilot Study to Assess the Effect, Safety, Tolerability a ...	Duchenne Muscular Dystrophy	Drug: PRO044 SC;Drug: PRO044 IV	BioMarin Pharmaceutical	NULL	Completed	5 Years	16 Years	Male	18	Phase 1/Phase 2	Belgium;Italy;Netherlands;Sweden

First Previous1Next Last